Company logo

ARAV - Aravive, Inc.

NASDAQ -> Healthcare -> Biotechnology
Houston, United States
Type: Equity

ARAV price evolution
ARAV
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Jan 2023
Current assets
Cash $10.94 $20.75 $38.38 $56.13
Short term investments
Net receivables $0.09
Inventory
Total current assets $9.56 $22.05 $39.06 $57.97
Long term investments
Property, plant & equipment $1.07 $1.3 $1.52 $1.73
Goodwill & intangible assets
Total noncurrent assets $3.49 $3.69 $3.98 $4.18
Total investments
Total assets $13.05 $25.74 $43.04 $62.15
Current liabilities
Accounts payable $5.42 $3.89 $9.79 $8.77
Deferred revenue $2.65 $3.61 $5.04
Short long term debt $2.12 $2.15 $2.17 $2.19
Total current liabilities $9.78 $14.22 $20.19 $22.11
Long term debt $0.31 $0.82 $1.35 $1.88
Total noncurrent liabilities $1.57 $31.33 $61.46 $29.38
Total debt $2.43 $2.97 $3.52 $4.08
Total liabilities $11.35 $45.55 $81.66 $51.5
Shareholders' equity
Retained earnings -$626.85 -$648.08 -$666.08 -$616.13
Other shareholder equity
Total shareholder equity $1.7 -$19.82 -$38.61 $10.66
(in millions $) 31 Jan 2023 31 Dec 2021 31 Dec 2020 31 Dec 2019
Current assets
Cash $56.13 $61.85 $62.97 $67.56
Short term investments
Net receivables $0.09 $0.03 $0.3 $2.5
Inventory
Total current assets $57.97 $62.74 $61.69 $68.21
Long term investments
Property, plant & equipment $1.73 $2.61 $3.48 $10.51
Goodwill & intangible assets $0.1 $0.22
Total noncurrent assets $4.18 $5.04 $6.02 $13.91
Total investments
Total assets $62.15 $67.79 $67.71 $82.12
Current liabilities
Accounts payable $8.77 $2.66 $2.5 $1.08
Deferred revenue $5.04 $8.12 $6.32
Short long term debt $2.19 $2.3 $2.09 $2.39
Total current liabilities $22.11 $17.94 $9.46 $4.97
Long term debt $1.88 $4.08 $6.43 $7.84
Total noncurrent liabilities $29.38 $7.62 $10.19 $8.1
Total debt $4.08 $6.37 $8.52 $10.23
Total liabilities $51.5 $25.57 $19.66 $13.07
Shareholders' equity
Retained earnings -$616.13 -$539.8 -$500.65 -$470.11
Other shareholder equity
Total shareholder equity $10.66 $42.22 $48.05 $69.05
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Revenue
Total revenue $2.76 $1.27 $1.49 $1.47
Cost of revenue
Gross Profit $2.76 $1.27 $1.49 $1.47
Operating activities
Research & development $8.73 $10.79 $15.91 $17.95
Selling, general & administrative $2.94 $3.07 $3.49 $3.38
Total operating expenses $11.67 $13.86 $19.4 $21.34
Operating income -$8.91 -$12.59 -$17.91 -$19.86
Income from continuing operations
EBIT $21.23 $18.01 -$49.96 -$29.13
Income tax expense
Interest expense
Net income
Net income $21.23 $18.01 -$49.96 -$29.13
Income (for common shares) $21.23 $18.01 -$49.96 -$29.13
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Revenue
Total revenue $9.14 $7.44 $5.68 $4.75
Cost of revenue
Gross Profit $9.14 $7.44 $5.68 $4.75
Operating activities
Research & development $66.94 $37.54 $17.62 $12.84
Selling, general & administrative $13.04 $10.55 $13.06 $13.69
Total operating expenses $79.97 $48.09 $36.47 $26.53
Operating income -$70.84 -$40.65 -$30.78 -$21.77
Income from continuing operations
EBIT -$76.32 -$39.15 -$30.54 -$18.22
Income tax expense
Interest expense
Net income
Net income -$76.32 -$39.15 -$30.54 -$18.22
Income (for common shares) -$76.32 -$39.15 -$30.54 -$18.22
(in millions $) 30 Sep 2023 30 Jun 2023 31 Mar 2023 31 Dec 2022
Net income $21.23 $18.01 -$49.96 -$29.13
Operating activities
Depreciation $0.22 $0.22 $0.21 $0.22
Business acquisitions & disposals
Stock-based compensation $0.29 $0.76 $0.69 $0.58
Total cash flows from operations -$9.81 -$17.66 -$17.75 -$14.24
Investing activities
Capital expenditures
Investments
Total cash flows from investing
Financing activities
Dividends paid
Sale and purchase of stock $0.03 $40.05
Net borrowings
Total cash flows from financing $0.03 $40.05
Effect of exchange rate
Change in cash and equivalents -$9.81 -$17.63 -$17.75 $25.8
(in millions $) 31 Dec 2022 31 Dec 2021 31 Dec 2020 31 Dec 2019
Net income -$76.32 -$39.15 -$30.54 -$18.22
Operating activities
Depreciation $0.89 $0.97 $1.83 $0.5
Business acquisitions & disposals
Stock-based compensation $2.56 $2.26 $1.97 $3.4
Total cash flows from operations -$65.08 -$32.18 -$12.17 -$17.08
Investing activities
Capital expenditures -$0.01
Investments
Total cash flows from investing -$0.01
Financing activities
Dividends paid
Sale and purchase of stock $59.37 $31.06 $7.58 $25.25
Net borrowings
Total cash flows from financing $59.37 $31.06 $7.58 $25.25
Effect of exchange rate
Change in cash and equivalents -$5.72 -$1.12 -$4.59 $8.17
Fundamentals
Market cap $2.95M
Enterprise value -$5.56M
Shares outstanding 73.60M
Revenue $7.00M
EBITDA -$38.97M
EBIT -$39.85M
Net Income -$39.85M
Revenue Q/Q -44.39%
Revenue Y/Y -19.11%
P/E ratio -0.07
EV/Sales -0.80
EV/EBITDA 0.14
EV/EBIT 0.14
P/S ratio 0.42
P/B ratio 1.74
Book/Share 0.02
Cash/Share 0.15
EPS -$0.54
ROA -110.70%
ROE 345.97%
Debt/Equity 4.83
Net debt/EBITDA -0.01
Current ratio 0.98
Quick ratio 0.98